Document is current
Any future updates will be listed below
-
Authors
Reinhardt, Christian
Harden, Markus
Herrmann-Lingen, Christoph
Rittmeyer, Achim
Andreas, Stefan https://orcid.org/0000-0003-3918-6909
-
Funding
Funding for this research was provided by:
Georg-August-Universität Göttingen
- License Information
-
More Information
Article History
Received: 14 March 2022
Accepted: 22 June 2022
First Online: 27 June 2022
Declarations
:
: The study was conducted in accordance with good clinical practice standards (GCP) and approved by the local ethics committee (Ethikkommission der Universitätsmedizin Göttingen, 16/3/14), the European PAS registry (EUPAS8748) and the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) (NIS-Studien-Nr. 5508) before enrolment. All patients provided written informed consent before study related procedures.
: Not applicable.
: CR reports personal fees from Boehringer, Roche, BerlinChemie, Jansen, Astra Zeneca und GSK outside the submitted work. AR reports grants from EliLilly, BMS, Boehringer Ingelheim, AstraZeneca, MSD, Pfizer, AbbVie, Novartis and Roche, outside the submitted work. SA reports grants and personal fees from Boehringer Ingelheim, personal fees from Novartis, AstraZeneca, GSK, Chiesi and Merini, outside the submitted work. The other authors declare that they have no competing interests.
